Abstract:The environmental risk assessment (ERA) for genetically modified plants (GMPs) is a prerequisite for commercial approval of these new varieties according to regulatory systems worldwide. The first country to regulate GM crops was the USA and the issue of possible environmental impacts was based on the principles used in risk assessment of pesticides. Two main pillars of this approach are the use of surrogate species for testing effects on non-target organisms using a tiered assessment with clear thresholds to indicate the need to move between tiers. The latest EFSA guidance document on ERA of Genetically Modified Organisms considers specifically the receiving environment in preparation of ERA for commercial cultivation of GMPs. According to existing guidelines in the EU, the receiving environment is defined by three mutually interacting components: the characteristics of the environmental stressor (i.e. the GM plant), the bio-geographical regions where the commercial release of the crop is expected and the agricultural systems therein. Difference in agronomic and ecological conditions (e.g. use of different varieties, vegetation of adjacent areas, non-target species assemblages, sensitivity of local species to the stressors) suggests that explicit considerations of the receiving environments are necessary. Results from field experiments indicate that differences in cultivation practices, e.g. the herbicide regime used on herbicide-tolerant GM crops, may induce direct and indirect effects on wild plant distribution and abundance, with consequent repercussions on food webs based on these plants. Moreover, ecological literature indicates that the concept of surrogate species has clear limitations if applied broadly to any ERA. Starting from case studies regarding GMPs, this paper discusses some ecological and agronomic characteristics of agro-ecosystems, which have implications in the elaboration of both hazard and exposure analyses during ERA. The species selection approach indicated in the EFSA Guidance Document and the consideration of the area(s) of the expected release of the new variety may provide the basis to an ecologically sound ERA for a range of environmental stressors. The quality of the data that become available for risk managers with this approach may support a more transparent and dependable ERA and risk management for GMPs as well as for other potential environmental stressors in agro-ecosystems.

European legislation for veterinary medicines: Would a monograph system improve the environmental risk assessment?

Improving the regulatory environmental risk assessment of human pharmaceuticals: Required changes in the new legislation

Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role

Assessment of ecological risks posed by veterinary antibiotics in European aquatic environments: A comprehensive review and analysis

Antibiotic residues in livestock manure: Does the EU risk assessment sufficiently protect against microbial toxicity and selection of resistant bacteria in the environment?

Improving Risk Assessment in the European Food Safety Authority: Lessons From the European Medicines Agency

EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)

Comparison of international legislation and standards on veterinary drug residues in food of animal origin

Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance

Defining the data gap: what do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment?

Environmental risk assessment in agro-ecosystems: Revisiting the concept of receiving environment after the EFSA guidance document

Advance in ecological environment impact of veterinary drug residues.

[Europe and medicines: role of the EMEA]

A systems-based analysis to rethink the European environmental risk assessment of regulated chemicals using pesticides as a pilot case

Critical review of the default values used in the environmental impact assessment of biocidal products applied in livestock production systems

Review and Analysis of National Monitoring Systems for Antimicrobial Resistance in Animal Bacterial Pathogens in Europe: A Basis for the Development of the European Antimicrobial Resistance Surveillance Network in Veterinary Medicine (EARS-Vet)

The environmental impact of pharmaceuticals: an evidence-mapping review of recent data on aquatic concentrations and predictable effects

Use of new scientific developments in regulatory risk assessments: challenges and opportunities

Pharmaceutical consumption in human and veterinary medicine in Germany: potential environmental challenges

The veterinary use of diclofenac and vulture conservation in Spain: Updated evidence and socio-ecological implications

A European nano-registry as a reliable database for quantitative risk assessment of nanomaterials? A comparison of national approaches